The FLOW trial The FLOW trial, published in the New England Journal of Medicine in 2024, tested subcutaneous semaglutide 1.0 mg (the Ozempic dose, not the higher Wegovy dose) in 3,533 people with type 2 diabetes and CKD
Sharifi-RadJSeidelVIzabelaMMonserrat-MequidaMSuredaAOrmazabalVet al
In practice, this combination would need to be evaluated by a supervising physician with careful monitoring
Clinical Quality in the Real World Both companies score well clinically, but patients should still think beyond the score headline
Until Es arrived, the grand total of my thoughts about aging could be summed up in a line my father likes to say: It sucks getting old, but it beats the alternative! Now as I stared into her little purple face, I wanted every healthy minute I could get
Why Choose Pure Med Spa Chicago for Semaglutide and Tirzepatide